Company news

Solvonis Therapeutics PLC news in 2026

Solvonis Therapeutics PLC's news releases, calls and decks from 2026, newest first.

View company

US Patent Office allows ketamine patent

November 5, 2026

Directorate change

October 30, 2026

Holding(s) in Company

October 16, 2026

MOU Reached with ICAD

October 13, 2026

Investor Webinar – 15 October 2026

October 6, 2026

Notification of Admission of Shares and TVR

September 30, 2026

Unaudited interim results

September 30, 2026

New Analysis Identifies Major AUD Breakthrough

September 29, 2026

Vital Patent milestone achieved– SVN 114

September 3, 2026

Solvonis Raises £1.3 Million

August 25, 2026

Solvonis to Present at WTR Conference

August 11, 2026

SVN-015 Advances into Further NIDA-Funded Studies

August 6, 2026

Research Coverage Initiation

July 13, 2026

Solvonis Announces Positive SVN-002 Bridging Data

June 23, 2026

Announces Positive Bridging Data Supporting

June 22, 2026

Solvonis Announces Result of AGM

June 19, 2026

CSO Speaks at National Research Meeting

May 5, 2026

Appointment of Water Tower Research

April 22, 2026

US CNS Executive Order

April 20, 2026

Granted U.S. Patent from PTSD Discovery Programme

April 8, 2026

SVN-114 selected for PTSD discovery programme

March 10, 2026

Expansion of SVN-015 into depression

January 28, 2026

US Patent allowance for PTSD discovery programme

January 7, 2026

Decks in 2026